VAR-101

VAR-101 is a topical small molecule inhibitor targeting atypical protein kinase C iota (aPKCi), developed primarily for the treatment of basal cell carcinoma (BCC). aPKCi is an oncogene implicated in multiple human cancers, including BCC, cutaneous T-cell lymphoma, non-small cell lung cancer, acute myeloid leukemia, colorectal cancer, and pancreatic cancer. The mechanism of action involves inhibition of aPKCi activity, which plays a role in regulating cancer-associated transcription factors such as GLI-1 and K-RAS. Preclinical studies have demonstrated dose-dependent anti-tumor activity in both murine and human BCC cell lines as well as other tumor models. VAR-101 is being developed to offer clinical utility as either a neoadjuvant or adjuvant therapy for BCC via topical administration[1][4][5][7].